A PYMNTS Company

European AI Imaging Firms Unite to Expand Global Reach in Fracture Detection

By  |  March 3, 2026

Two European medical technology companies are combining their expertise in artificial intelligence to strengthen their position in the growing musculoskeletal imaging market, with a focus on improving the diagnosis and management of osteoporosis and bone fractures.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Switzerland-based Medimaps Group S.A. and Denmark-based Radiobotics ApS announced March 2 that they have agreed to merge. Financial details of the transaction were not disclosed.

    According to Fierce Biotech, the deal is designed to broaden the companies’ global footprint and bring together complementary AI-driven technologies aimed at enhancing both fracture detection and long-term risk assessment. Medimaps is known for its bone microarchitecture imaging tools, including TBS Osteo and TBS Reveal, which are used to evaluate fracture risk in patients with osteoporosis. Radiobotics, meanwhile, offers RBfracture, an AI solution that identifies subtle fractures and trauma-related findings on X-rays.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    By uniting these platforms, the companies aim to bridge what they describe as a divide between reactive diagnosis and preventative care. Per Fierce Biotech, the combined organization intends to create what it calls the first comprehensive AI ecosystem for musculoskeletal imaging, transforming routine X-rays into tools capable of both identifying acute injuries and predicting future fracture risk.

    “Our ambition is to give radiologists a single, trusted platform that brings together fracture detection and fracture risk prediction across the continuum of care,” said Didier Hans, Ph.D., co-founder and CEO of Medimaps Group, in a statement.

    The merged entity will maintain both Medimaps and Radiobotics as distinct brands, operating under a unified executive leadership team. According to Fierce Biotech, the integration is expected to extend the companies’ commercial presence to hospitals, clinics and imaging centers in more than 90 countries.

    Radiobotics CEO Peter Ulvskjold emphasized the potential impact on patient access to advanced imaging tools. The merger “will accelerate access to our technology” and represents “an important step in our vision to ensure patients receive immediate and precise, expert-level care in MSK imaging, 24/7, regardless of time, infrastructure or staffing constraints,” he said in a statement.

    The transaction also has strategic implications for regulatory expansion. Per Fierce Biotech, Radiobotics plans to utilize Medimaps’ U.S. office as it prepares to introduce RBfracture to the American market, where the company anticipates securing FDA clearance by the end of the year. At the same time, Medimaps intends to leverage Radiobotics’ Danish base to streamline CE registration processes for upcoming products in Europe.

    Source: Fierce Biotech